Aeterna Zentaris Inc.
) source of revenue includes sales, royalties and license fees.
Sales are derived from Cetrotide and royalties are derived
) net sales of Cetrotide.
License fees include periodic milestone payments, research and
development contract fees and the amortization of upfront
payments received from licensing partners. Merck KGaA's
subsidiary Merck Serono markets Cetrotide globally (excluding
Cetrotide is a luteinizing hormone-releasing hormone (LHRH)
antagonist treatment approved for in vitro fertilization. Sales
and royalties for the quarter ended Jun 2013 were $29.8
In Apr 2013, Aeterna Zentaris had entered into an agreement
with Merck KGaA to grant the latter manufacturing license and
transfer manufacturing rights of Cetrotide. This agreement was
completed in Oct 2013. As per the deal, Merck KGaA will pay a
one-time payment of €2.5 million/ $3.3 million to Aeterna
In Nov 2008, Aeterna Zentaris had monetized the royalty stream
related to Cetrotide in a transaction with HealthCare Royalty
We note that Cetrotide is marketed in 3 mg and 0.25 mg dosages
by Merck Serono in the U.S. and Europe. It was launched in Japan
in Sep 2006. It is marketed in Japan by its partner
Aeterna Zentaris has its focus on developing AEZS-108,
AEZS-130 and AEZS-120. AEZS-108 is in a phase III ZoptEC
study for the treatment of endometrial cancer and in phase II
studies for the treatment of breast, prostate and bladder cancer.
The company intends to seek U.S. approval for AEZS-130 for growth
hormone deficiency. Aeterna Zentaris will commence a phase I
study on AEZS-120 for treating prostate cancer.
Aeterna Zentaris currently carries a Zacks Rank #3 (Hold).
Currently, companies like
) look more attractive with a Zacks Rank #1 (Strong Buy).
AETERNA ZENTARS (AEZS): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
MERCK KGAA (MKGAF): Get Free Report
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.